Candriam S.C.A. Increases Position in BioNTech SE (NASDAQ:BNTX)

Candriam S.C.A. increased its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 261.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 578,998 shares of the company's stock after buying an additional 418,695 shares during the quarter. Candriam S.C.A. owned about 0.24% of BioNTech worth $46,526,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in BNTX. GAMMA Investing LLC lifted its position in BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company's stock valued at $25,000 after purchasing an additional 150 shares during the period. CWM LLC lifted its position in BioNTech by 657.6% during the fourth quarter. CWM LLC now owns 250 shares of the company's stock valued at $26,000 after purchasing an additional 217 shares during the period. Frazier Financial Advisors LLC acquired a new position in BioNTech during the fourth quarter valued at $30,000. Covestor Ltd lifted its position in BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company's stock valued at $38,000 after purchasing an additional 133 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its position in BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company's stock valued at $43,000 after purchasing an additional 252 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. decreased their target price on shares of BioNTech from $94.00 to $91.00 and set an "underweight" rating for the company in a research report on Thursday, August 15th. Deutsche Bank Aktiengesellschaft upgraded shares of BioNTech from a "hold" rating to a "buy" rating and set a $95.00 price objective for the company in a research report on Wednesday, August 7th. HSBC upgraded shares of BioNTech from a "hold" rating to a "buy" rating in a research report on Friday, August 2nd. TD Cowen decreased their price objective on shares of BioNTech from $98.00 to $85.00 and set a "hold" rating for the company in a research report on Tuesday, August 6th. Finally, Evercore ISI started coverage on shares of BioNTech in a research report on Tuesday, May 14th. They issued an "inline" rating and a $100.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $109.09.

BioNTech Price Performance

Shares of BNTX traded down $0.21 during mid-day trading on Friday, hitting $89.94. 654,893 shares of the company were exchanged, compared to its average volume of 692,243. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $121.39. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. The company has a 50 day moving average of $84.65 and a 200-day moving average of $89.23. The stock has a market cap of $21.38 billion, a price-to-earnings ratio of 179.88 and a beta of 0.23.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The company had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. During the same quarter last year, the company earned ($0.86) EPS. The firm's revenue for the quarter was down 23.3% on a year-over-year basis. Analysts expect that BioNTech SE will post -2.8 EPS for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.